HIV Treatment as Prevention: Issues in Economic Evaluation
TLDR
Economic evaluations of antiretroviral therapy in currently existing programs and in HIV treatment as prevention (TasP) programs should use cost functions that capture cost dependence on a number of factors, such as scale and scope of delivery.Abstract:
Meyer-Rath and Over assert in another article in the July 2012 PLoS Medicine Collection, “Investigating the Impact of Treatment on New HIV Infections”, that economic evaluations of antiretroviral therapy (ART) in currently existing programs and in HIV treatment as prevention (TasP) programs should use cost functions that capture cost dependence on a number of factors, such as scale and scope of delivery, health states, ART regimens, health workers' experience, patients' time on treatment, and the distribution of delivery across public and private sectors. We argue that for particular evaluation purposes (e.g., to establish the social value of TasP) and from particular perspectives (e.g., national health policy makers) less detailed cost functions may be sufficient. We then extend the discussion of economic evaluation of TasP, describing why ART outcomes and costs assessed in currently existing programs are unlikely to be generalizable to TasP programs for several fundamental reasons. First, to achieve frequent, widespread HIV testing and high uptake of ART immediately following an HIV diagnosis, TasP programs will require components that are not present in current ART programs and whose costs are not included in current estimates. Second, the early initiation of ART under TasP will change not only patients' disease courses and treatment experiences—which can affect behaviors that determine clinical treatment success, such as ART adherence and retention—but also quality of life and economic outcomes for HIV-infected individuals. Third, the preventive effects of TasP are likely to alter the composition of the HIV-infected population over time, changing its biological and behavioral characteristics and leading to different costs and outcomes for ART.read more
Citations
More filters
Journal ArticleDOI
Interventions to improve adherence to antiretroviral therapy: a rapid systematic review
Krisda H. Chaiyachati,Osondu Ogbuoji,Matthew Price,Amitabh B. Suthar,Eyerusalem K. Negussie,Till Bärnighausen +5 more
TL;DR: A rapid systematic review of the global evidence on interventions that can improve adherence to ART, including individual-level interventions and changes to the structure of ART delivery, to inform the evidence base for the 2013 WHO consolidated antiretroviral guidelines.
Journal ArticleDOI
Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest?
Ann M Dennis,Joshua T. Herbeck,Andrew J. Leigh Brown,Paul Kellam,Paul Kellam,Tulio de Oliveira,Deenan Pillay,Christophe Fraser,Myron S. Cohen +8 more
TL;DR: This work describes the current uses for phylogenetics in generalized epidemics and discusses their promise for elucidating transmission patterns and informing prevention trials, and reviews logistic and technical challenges inherent to large-scale molecular epidemiological studies of generalized Epidemics and suggest potential solutions.
Journal ArticleDOI
Economics of antiretroviral treatment vs. circumcision for HIV prevention
TL;DR: A new mathematical model is developed and applied to South Africa, finding that high ART coverage combined with high MMC coverage provides approximately the same HIV incidence reduction as TasP, for $5 billion less over 2009–2020.
Journal ArticleDOI
HIV Treatment as Prevention: Models, Data, and Questions - Towards Evidence-Based Decision-Making
TL;DR: It is hoped that this article will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.
Journal ArticleDOI
Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk.
Ailsa R. Butler,Jennifer A. Smith,Chelsea B. Polis,Simon Gregson,David C. Stanton,Timothy B. Hallett +5 more
TL;DR: If IHC use increases HIV acquisition risk, reducing IHC could reduce new HIV infections; however, this must be balanced against other important consequences, including unintended pregnancy, which impacts maternal and infant mortality.
References
More filters
Journal ArticleDOI
Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India.
Lorna Guinness,Lilani Kumaranayake,Bhuvaneswari Rajaraman,Girija Sankaranarayanan,Gangadhar Vannela,P. Raghupathi,Alex George +6 more
TL;DR: Average costs vary with the scale of the project, highlighting the importance of improving scale-specific cost information for planning.
Journal ArticleDOI
Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.
Arthi Vijayaraghavan,Molly B. Efrusy,Peter Mazonson,Osman Ebrahim,Ian Sanne,Christopher C. Santas +5 more
TL;DR: Treating patients with HIV according to developed versus developing world guidelines is highly cost-effective and may result in substantial long-term savings.
Journal ArticleDOI
Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa.
TL;DR: Patients who have initiated ART reported significantly less functional impairment, fewer symptoms, and better work performance than those who had not yet started treatment, however.
Journal ArticleDOI
The associations among coping, nadir CD4+ T-cell count, and non-HIV-related variables with health-related quality of life among an ambulatory HIV-positive patient population
TL;DR: Factors independently associated with lower MHS and lower PHS include lower nadir CD4+ T-cell counts, and use of maladaptive coping.
Journal ArticleDOI
Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence
TL;DR: Future studies need to test the effectiveness of interventions to increase testing and treatment uptake, retention, and adherence under TasP, that is, ART for all HIV-infected individuals, independent of disease stage.
Related Papers (5)
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Sanjay Mehendale,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Lei Wang,Joseph Makhema,Lisa A. Mills,Guy de Bruyn,Ian Sanne,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Heather J. Ribaudo,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Myron Essex,Thomas R. Fleming +34 more
HIV treatment as prevention: Systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa
Jeffrey W. Eaton,Leigh F. Johnson,Joshua A. Salomon,Till Bärnighausen,Till Bärnighausen,Eran Bendavid,Anna Bershteyn,David E. Bloom,Valentina Cambiano,Christophe Fraser,Jan A. C. Hontelez,Salal Humair,Salal Humair,Daniel J. Klein,Elisa F Long,Andrew N. Phillips,Carel Pretorius,John Stover,Edward Allen Wenger,Brian G. Williams,Timothy B. Hallett +20 more